Mabwell has dosed the first patient in its Phase II anti-IL-11 antibody (9MW3811) clinical trial in China for pathological scarring.
This marks the first time an IL-11 targeted drug candidate has entered clinical trials for this indication globally.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Phase II clinical trial is designed to evaluate the tolerability, safety, preliminary efficacy, and pharmacokinetics of 9MW3811.
The first patient received dosing at Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine.
Mabwell previously completed Phase I trials with 9MW3811 in healthy patients in China and Australia, reporting a favourable safety profile and a half-life of more than a month.
Interleukin-11 (IL-11) is a cytokine involved in fibrosis-related diseases and chronic inflammation, playing a role in the fibrosis process of multiple organs.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAccording to Mabwell, preclinical research has shown that 9MW3811 demonstrated marked efficacy in models such as pulmonary fibrosis and has potential application in fibrosis-related diseases like abnormal endometrial bleeding and hypertrophic scar.
In human-derived keloid animal models, 9MW3811 alleviated the skin fibrosis process and reduced the volume of established scars.
There are currently no effective therapeutic drugs for hypertrophic scars and keloids, revealing a significant unmet clinical need.
Mabwell noted that 9MW3811 will offer new treatment options for patients with these conditions.
Mabwell is a biopharmaceutical company with capabilities across the pharmaceutical value chain, focusing on ageing-related diseases and oncology.
In August 2024, the company received approval from China’s National Medical Products Administration (NMPA) to begin a Phase III clinical trial of 9MW2821 plus Toripalimab for treating urothelial carcinoma.
